[1] BROWN G D, DENNING D W, GOW N A,et al. Hidden killers: Human fungal infections[J]. Sci Transl Med,2012, 4(165):165rv13.
[2] BONGOMIN F, GAGO S, OLADELE R O, et al. Global and multi-national prevalence of fungal diseases-estimate precision[J].J Fungi (Basel), 2017, 3(4):57.
[3] GALLAGHER J C, DODDS ASHLEY E S, DREW R H,et al.Antifungal pharmacotherapy for invasive mould infections[J]. Expert Opin Pharmacother, 2003, 4(2): 147-164.
[4] LIVERMORE J, HOPE W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections[J]. Expert Opin Drug Metab Toxicol, 2012, 8(6):759-765.
[5] JENKS J D, SALZER H J, PRATTES J, et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: Design, development, and place in therapy[J]. Drug Des Dev Ther,2018,12:1033-1044. DOI:10.2147/DDDT.S145545.
[6] SCHMITT-HOFFMANN A, DESAI A, KOWALSKI D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH[J]. Int. J Clin Pharmacol Ther,2016,54(8):572-580.
[7] KOVANDA L L, MARTY F M, MAERTENS J, et al. Impact of mucositis on absorption and systemic drug exposure of isavuconazole[J]. Antimicrob Agents Chemother,2017,61(6):e00101-17.
[8] SCHMITT-HOFFMANN A, ROOS B, HEEP M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers[J]. Antimicrob Agents Chemother,2006,50(1):279-285.
[9] SCHMITT-HOFFMANN A, ROOS B, MAARES J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers[J]. Antimicrob Agents Chemother,2006,50(1):286-293.
[10] EVERSON N,SMITH J, GARNER D. Successful treatment of contaminated epidural steroid associated fungal menigitis with isauvconazole. In proceedings of the European Congress of Clinical Microbiology And Infectious Disease (ECCMID)[J].Ann Clin Microbiol Antimicrob,2022,21(1):42.
[11] SCHMITT-HOFFMANN A H, KATO K, TOWNSEND R,et al.Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats[J]. Antimicrob Agents Chemother,2017,61(12):e01292-17.
[12] KOVANDA L L, DESAI A V, LU Q, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)[J]. Antimicrob Agents Chemother,2016,60(8):4568-4576.
[13] KAINDL T,ANDES D, ENGELHARDT M,et al.Variability and exposure-response relationships of isavuconazole plasma concentrations in the phase 3 SECURE trial of patients with invasive mould diseases[J]. Antimicrob Chemother,2019,74(3):761-767.
[14] TOWNSEND R W,AKHTAR S,ALCORN H,et al.Phase Ⅰ trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics[J]. Eur J Clin Pharmacol,2017,73(6):669-678.
[15] ZURL C,WALLER M,SCHWAMEIS F,et al.Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: Outcome, tolerability and clinical implications of isavuconazole plasma concentrations[J]. J Fungi,2020,6(2):90.
[16] ZHAO Y,SEELHAMMER T G, BARRETO E F,et al. Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation[J]. Pharmacotherapy,2020,40(1):89-95.
[17] ANDES D,KOVANDA L,DESAI A,et al.Isavuconazole concentration in real-world practice: Consistency with results from clinical trials[J]. Antimicrob Agents Chemother,2018,62(7):e00585-18.
[18] PATTERSON T F, THOMPSON G R,DENNING D W,et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016,63(4):433-442.
[19] TISSOT F, AGRAWAL S, PAGANO L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J]. Haematologica,2017,102(3):433-444.
[20] GUINEA J, PELÁEZ T, RECIO S,et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species[J]. Antimicrob Agents Chemother,2008,52(4):1396-1400.
[21] ASTVAD K M T, HARE R K,ARENDRUP M C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates[J]. Clin Microbiol Infect,2017,23(11):882-887.
[22] SEIFERT H, AURBACH U,STEFANIK D,et al. In vitro activities of isavuconazole and other antifungal agents against candida bloodstream isolates. antimicrob[J]. Agents Chemother,2007,51(5):1818-1821.
[23] ESPINEL-INGROFF A,CHOWDHARY A,GONZALEZ G M,et al.Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method[J]. Antimicrob Agents Chemother,2015,59(1):666-668.
[24] OSEI SEKYERE J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen[J]. Microbiologyopen,2018, 7(4):e00578.
[25] DATTA K, RHEE P, BYRNES E,et al.Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility[J]. J Clin Microbiol,2013,51(9):3090-3093.
[26] ARENDRUP M C,JENSEN R H, Meletiadis, J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order[J]. Antimicrob Agents Chemother,2015,59(12):7735-7742.
[27] Astellas Pharma US & Inc. CRESEMBA (isavuconazonium_sulfate) Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf.
[28] KIEU V,JHANGIANI K, DADWAL S,et al.Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study[J]. Transpl Infect Dis,2019,21(1):e13007.
[29] KONTOYIANNIS D P,MARR K A,PARK B J,et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance network (TRANSNET) database[J]. Clin Infect Dis,2010, 50(8):1091-1100.
[30] MAERTENS J A, RAAD I I, MARR K A,et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial[J]. Lancet,2016,387(10020):760-769.
[31] BONGOMIN F, MAGUIRE N, MOORE C B,et al.Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events[J]. Mycoses,2019,62(3):217-222.
[32] HARRINGTON R,LEE E, YANG H,et al.Cost-effectiveness analysis of isavuconazole vs. voriconazole as first-line treatment for invasive aspergillosis[J]. Adv Ther,2017,34(1):207-220.
[33] FLOROS L, PAGLIUCA A, TAIE A A,et al. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom[J]. J Med Econ,2020,23(1):86-97.
[34] FLOROS L, KUESSNER D, POSTHUMUS J,et al.Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden[J]. BMC Infect Dis,2019,19(1):134.
[35] ULLMANN A J, AGUADO J M, ARIKAN-AKDAGLI S,et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect,2018,24 (Suppl 1):e1-e38.
[36] PETRIKKOS G, SKIADA A,LORTHOLARY O,et al. Epidemiology and clinical manifestations of mucormycosis[J]. Clin Infect Dis,2012,54 (Suppl 1):S23-S34.
[37] PERFECT J R, CORNELY O A, HEEP M,et al.Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial[J]. Mycoses,2018,61(7):420-429.
[38] MARTY F M, OSTROSKY-ZEICHNER L, CORNELY O A,et al.VITAL and fungiscope mucormycosis investigators. isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis,2016,16(7):828-837.
[39] ASHKENAZI-HOFFNUNG L,BILAVSKY E,LEVY I,et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients[J]. Pediatr Infect Dis,2020,39(8):718-724.
[40] ILHARCO M, PEREIRA C M, MOREIRA L,et al. Rhinoorbital mucormycosis in the immunocompetent: experience with isavuconazole[J]. IDCases, 2019,18:e00591. DOI: 10.1016/j.idcr.2019.e00591.
[41] SHAFIQ M, ALI Z, UKANI R,et al.Isavuconazole: A promising salvage therapy for invasive mucormycosis[J]. Cureus,2018,10(4):e2547.
[42] RICOTTA E E, LAI Y L, BABIKER A,et al. Invasive candidiasis species distribution and trends, United States[J]. Infect Dis, 2021,223(7):1295-1302.
[43] PFALLER M A, DIEKEMA D J. Epidemiology of invasive candidiasis: A persistent public health problem[J]. Clin Microbiol Rev,2007,20(1):133-163.
[44] KULLBERG B J, VISCOLI C, PAPPAS P G,et al.Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE trial[J]. Clin Infect Dis,2019,68(12):1981-1989.
[45] KEIRNS J, DESAI A, KOWALSKI D,et al. QT interval shortening with isavuconazole: In vitro and in vivo effects on cardiac repolarization[J]. Clin Pharmacol Ther,2017,101(6):782-790.
[46] MELLINGHOFF S C, BASSETTI M, DÖRFEL D,et al.Isavuconazole shortens the QT interval[J]. Mycoses,2018,61(4):256-260.
[47] WILSON D T, DIMONDI V P, JOHNSON S W,et al.Role of isavuconazole in the treatment of invasive fungal infections[J]. Ther Clin Risk Manag,2016,12:1197-1206.DOI: 10.2147/TCRM.S90335. eCollection 2016.
[48] SANGLARD D,COSTE A T. Activity of isavuconazole and other azoles against candida clinical isolates and yeast model systems with known azole resistance mechanisms[J]. Antimicrob Agents Chemother,2015,60(1):229-238.
[49] JØRGENSEN K M, ASTVAD K M T,HARE R K,et al. EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates[J]. Antimicrob Agents Chemother,2019,63(6):e00073-19. |
